Emerging Themes for the Role of Antibodies in Tuberculosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The best way to debunk a scientific dogma is to throw irrefutable evidence at it. This is especially true if the dogma in question has been nurtured over many decades, as is the case with the apparent redundancy of antibodies (Abs) against intracellular pathogens. Although not fully compelling yet, that ‘hard core’ evidence is nevertheless now slowly beginning to emerge. This is true for several clinically relevant infections but none more so than Mycobacterium tuberculosis, the archetype intracellular pathogen that poses a great health challenge to the mankind. Here, prompted by a spate of recent high-profile reports on the effects of Abs in various experimental models of tuberculosis, we step back and take a critical look at the progress that has been made in the last 5 years and highlight some of the strengths and shortcomings of the presented evidence. We conclude that the tide of the opinion has begun to turn in favour of Abs but we also caution against overinterpreting the currently available limited evidence. For, until definitive evidence that can withstand even the most rigorous of experimental tests is produced, the dogma may yet survive. Or indeed, we may find that the truth is hidden somewhere in between the dogma and the unfulfilled scientific prophecy.
Abstract
The best way to debunk a scientific dogma is to throw irrefutable evidence at it. This is especially true if the dogma in question has been nurtured over many decades, as is the case with the apparent redundancy of antibodies (Abs) against intracellular pathogens. Although not fully compelling yet, that ‘hard core’ evidence is nevertheless now slowly beginning to emerge. This is true for several clinically relevant infections but none more so than Mycobacterium tuberculosis, the archetype intracellular pathogen that poses a great health challenge to the mankind. Here, prompted by a spate of recent high-profile reports on the effects of Abs in various experimental models of tuberculosis, we step back and take a critical look at the progress that has been made in the last 5 years and highlight some of the strengths and shortcomings of the presented evidence. We conclude that the tide of the opinion has begun to turn in favour of Abs but we also caution against overinterpreting the currently available limited evidence. For, until definitive evidence that can withstand even the most rigorous of experimental tests is produced, the dogma may yet survive. Or indeed, we may find that the truth is hidden somewhere in between the dogma and the unfulfilled scientific prophecy.
참고문헌 (50)
- Global Tuberculosis Report 2018, "World Health Organisation (WHO)", WHO, ~ (2018)
- Peter Andersen, "Moving tuberculosis vaccines from theory to practice", Nature Reviews Immunology, 19(9), pp.550~562 (2019), Springer Science and Business Media LLC[DOI]
- Ottenhoff TH, "The knowns and unknowns of the immunopathogenesis of tuberculosis", Int J Tuberc Lung Dis, 16, pp.1424~1432 (2012)
- Achkar JM, "Antibody-mediated immunity against tuberculosis: implications for vaccine development", Cell Host Microbe, 13, pp.250~262 (2013)
- Jacobs AJ, "Antibodies and tuberculosis", Tuberculosis (Edinb), 101, pp.102~113 (2016)
- Scolnik PA, "mAbs: a business perspective", MAbs, 1, pp.179~184 (2009)
- Fine PE, "Variation in protection by BCG: implications of and for heterologous immunity", Lancet, 346, pp.1339~1345 (1995)
- Freer G, "Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies", New Microbiol, 41, pp.95~105 (2018)
- Lu LL, "A functional role for antibodies in tuberculosis", Cell, 167, pp.433~443.e14 (2016)
- McEwan WA, "Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21", Nat Immunol, 14, pp.327~336 (2013)
- Li H, "Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis", Proc Natl Acad Sci U S A, 114, pp.5023~5028 (2017)
- Overdijk MB, "Crosstalk between human IgG isotypes and murine effector cells", J Immunol, 189, pp.3430~3438 (2012)
- Zimmermann N, "Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis", EMBO Mol Med, 8, pp.1325~1339 (2016)
- Ferrara C, "Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose", Proc Natl Acad Sci U S A, 108, pp.12669~12674 (2011)
- Kumagai T, "Serum IgM glycosylation associated with tuberculosis infection in mice", mSphere, 4, pp.e00684~e00618 (2019)
- Williams A, "Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs", Immunology, 111, pp.328~333 (2004)
- Reljic R, "Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection", Clin Exp Immunol, 143, pp.467~473 (2006)
- Balu S, "A novel human IgA monoclonal antibody protects against tuberculosis", J Immunol, 186, pp.3113~3119 (2011)
- Buccheri S, "Prevention of the postchemotherapy relapse of tuberculous infection by combined immunotherapy", Tuberculosis (Edinb), 89, pp.91~94 (2009)
- Vasudeva-Rao HM, "Expression of the Mycobacterium tuberculosis acr-coregulated genes from the DevR (DosR) regulon is controlled by multiple levels of regulation", Infect Immun, 76, pp.2478~2489 (2008)
- Yuan Y, "The 16-kDa alphacrystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages", Proc Natl Acad Sci U S A, 95, pp.9578~9583 (1998)
- van Egmond M, "The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis", Immunol Lett, 68, pp.83~87 (1999)
- van Vuuren AJ, "Characterization of the human myeloid IgA Fc receptor I (CD89) gene in a cosmid clone", Immunogenetics, 49, pp.586~589 (1999)
- Reljic R, "In search of the elusive mouse macrophage Fc-alpha receptor", Immunol Lett, 107, pp.80~81 (2006)
- Chambers MA, "Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge", FEMS Immunol Med Microbiol, 41, pp.93~100 (2004)
- Hamasur B, "mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis", Clin Exp Immunol, 138, pp.30~38 (2004)
- Teitelbaum R, "A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival", Proc Natl Acad Sci U S A, 95, pp.15688~15693 (1998)
- de Vallière S, "Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies", Infect Immun, 73, pp.6711~6720 (2005)
- Guirado E, "Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice", Microbes Infect, 8, pp.1252~1259 (2006)
- Pethe K, "The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination", Nature, 412, pp.190~194 (2001)
- Prados-Rosales R, "Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine", PLoS Pathog, 13, pp.e1006250~ (2017)
- Copland A, "Mucosal delivery of fusion proteins with Bacillus subtilis spores enhances protection against tuberculosis by Bacillus Calmette-Guérin", Front Immunol, 9, pp.346~ (2018)
- Dietrich J, "Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity", J Immunol, 177, pp.6353~6360 (2006)
- D'Souza S, "Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis", Infect Immun, 71, pp.483~493 (2003)
- Geluk A, "Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans", J Immunol, 165, pp.6463~6471 (2000)
- Hart P, "Nanoparticle-fusion protein complexes protect against Mycobacterium tuberculosis infection", Mol Ther, 26, pp.822~833 (2018)
- van Dissel JT, "Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection", Vaccine, 29, pp.2100~2109 (2011)
- Ernst JD, "Dynamics of Mycobacterium tuberculosis Ag85B revealed by a sensitive enzyme-linked immunosorbent assay", MBio, 10, pp.e00611~e00619 (2019)
- Chen T, "Association of human antibodies to arabinomannan with enhanced mycobacterial opsonophagocytosis and intracellular growth reduction", J Infect Dis, 214, pp.300~310 (2016)
- Armstrong JA, "Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival", J Exp Med, 142, pp.1~16 (1975)
- Vergne I, "Cell biology of Mycobacterium tuberculosis phagosome", Annu Rev Cell Dev Biol, 20, pp.367~394 (2004)
- Coppola M, "Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression", Tuberculosis (Edinb), 106, pp.25~32 (2017)
- Grosset J, "Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary", Antimicrob Agents Chemother, 47, pp.833~836 (2003)
- Brady LJ, "Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens", Infect Immun, 73, pp.671~678 (2005)
- Pepponi I, "Immunecomplex mimics as a molecular platform for adjuvant-free vaccine delivery", PLoS One, 8, pp.e60855~ (2013)
- Reljic R, "IFN-gamma therapy of tuberculosis and related infections", J Interferon Cytokine Res, 27, pp.353~364 (2007)
- Khera AK, "Role of B cells in mucosal vaccine-induced protective CD8+ T cell immunity against pulmonary tuberculosis", J Immunol, 195, pp.2900~2907 (2015)
- Vordermeier HM, "Increase of tuberculous infection in the organs of B cell-deficient mice", Clin Exp Immunol, 106, pp.312~316 (1996)
- Phuah JY, "Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis", Am J Pathol, 181, pp.508~514 (2012)
- Loxton AG, "Bcells and their regulatory functions during tuberculosis: latency and active disease", Mol Immunol, 111, pp.145~151 (2019)